NouvNeu001 — Human Dopaminergic Progenitor Cells for Parkinson's Disease, Phase 1/2
—
| Trial ID | NCT07102342 ↗ |
|---|---|
| Sponsor | iRegene Therapeutics Co., Ltd. · China |
| Cell Source | dopaminergic-progenitor · allogeneic |
| Indication | 파킨슨병 · Parkinson's Disease |
| Phase | PHASE 1 2 |
| Status | RECRUITING |
| Delivery Route | intracerebral cell transplantation |
| Enrollment | 5 |
| Publication | — |
Trial Design
NouvNeu001 is a Phase 1/2 study evaluating the safety, tolerability, feasibility, and preliminary efficacy of intracerebral transplantation of human dopaminergic progenitor cells in patients with Parkinson’s disease. The enrolled population is very small, at five participants. The primary endpoints are adverse events and serious adverse events. Secondary endpoints include changes in MDS-UPDRS Parts I–IV.
Clinical Significance
Loss of dopaminergic neurons is a defining pathological feature of Parkinson’s disease. An approach that delivers dopaminergic progenitor cells to restore compromised neurological function therefore holds meaningful implications for neural regeneration. While this study is not designed to confirm efficacy, it reflects the expansion of iPSC- and progenitor cell-based therapies into the domain of neurological disease.
Reasons NouvNeu001 is drawing attention:
- Disease-specific cell therapy — dopaminergic progenitor cells with direct relevance to Parkinson’s pathology
- Neural regeneration approach — exploring the possibility of functional recovery beyond symptom management
- Long-term follow-up needed — to observe engraftment, aberrant proliferation, and motor function changes
- Early clinical stage — safety and feasibility are the primary focus
Limitations and Discussion
With only five participants, it is too early to draw conclusions about treatment efficacy. Engraftment, long-term safety, dyskinesia, and the potential for neoplastic transformation must all be evaluated over extended follow-up. The full clinical value in Parkinson’s disease will also require assessment of gait, balance, fall risk, and activities of daily living — not MDS-UPDRS scores alone.